CEDNA BIOTECH
Cedna Biotech is a dynamic, innovative pharmaceutical company that cares about the health and well being of people across the Globe. In very short span of time we succeeded in developing complex innovative medicines especially for critical care.
Our product and facilities are compliant with the WHO, GMP Standards to maintain our reputation for high quality and optimal performance.
We are known for our on-site quality control and state of the art laboratory facilities having the latest and most sophisticated analytical equipment, which allow us to further support our commitment to high quality manufacturing.
read moreOur Vision
Our vision is to become the top player of the pharmaceutical market that serves the top class range of quality products in the market which is affordable and effective to the patient.
Our Mission
At Cedna Biotech, we are committed to discover, develop and market novel products, which enhance patient well-being. Our goal is to deliver a wide range of high quality pharmaceutical products and services within reach of every patient.
Our Values
- Achieving customer satisfaction is fundamental to our business
- Provide products and services of the highest quality
- Manage our operations with high concern for safety and environment
- Practice dignity and equity in relationships and provide opportunities for our people to realise their full potential
Our Products
Satisfied Clients
Medical Products
Years of Excellence
Countries using products
Manufacturing facilities
Cedna’s manufacturing operations is located at Baddi, Himachal Pradesh, India. This Manufacturing unit is WHO GMP certified by SDA (State Drug Administration). The Manufacturing unit has a heating ventilation air conditioning and cold storage rooms for better hygienic conditions suitable to manufacture sterile products and their storage.
We believe that Quality and Regulatory Compliance not only have to be embedded into the product but have to be built into people, systems, and processes through a systematic process of continuous training and knowledge sharing.
As we aspire to further accelerate and scale higher orbits of growth, we are conscious of the fact that product and market complexity will increase exponentially. We are aware that the Company needs to stay ahead of the curve by continuously investing in new technology, automation and systems to create better efficiencies that enhance profitability.
Manufacturing facilities
Ashok
I recently found myself under your care for a cardiac issue. While there, accompanied by my wife, we found that the entire staff at Jamaica Hospital was exceedingly professional and efficient, from your E.R. receptionists to the cardiac care team. You should be proud of your outstanding staff and service.
Rohan
On behalf of my wife, who was a patient in your hospital, I humbly submit my sincere gratitude to the management and staff of Jamaica Hospital, especially to your outstanding nurses and PCAs. They have been outstandingly helpful and provided a high quality of service, care and comfort to my wife. Thank you.
Jena Karlis
I am writing to express my gratitude from my family for the care given to my mother. In the SICU, there was care, compassion, and respect. A special thank you to your social workers as well; they provided professional guidance, comfort, and strength to make our own decisions. Finally, I cannot praise the Palliative Care and Hospice team enough. They were patient and helpful. All our hope that you continue along this path.
Matt Brandon
Fugiat enim eram quae cillum dolore dolor amet nulla culpa multos export minim fugiat minim velit minim dolor enim duis veniam ipsum anim magna sunt elit fore quem dolore labore illum veniam.
John Larson
I was recently cared for at Jamaica Hospital following a heart attack while at JFK. I just wanted to say a few words about the exceptional care I received in the Jamaica Hospital Cardiac Care Unit and the MICU. All of the doctors and nurses were friendly, pleasant, kind, thorough, conscientious and professional. I am happy to have been in their care.
Latest Articles
With Revlimid sales down, BMS slashes 2023 revenue projection
BMS has sliced its 2023 sales projection for Revlimid by a whopping $1 billion and cut its overall revenue projection from a 2% increase to a decline.
Admin 27, 2023 11:08pmLilly, BI's Jardiance scores EU nod in chronic kidney disease
After recent label expansions paid off with a sizable sales increase for Jardiance, the drug has added a third use to its European label.
Admin 27, 2023 11:08pmUK probes GLP-1 drugs' potential suicide risks: Reuters
Following in European regulators' footsteps, the U.K. has launched a probe into potential suicide risks for popular diabetes and weight-loss drugs.
Admin 27, 2023 11:08pm